NCT02111889View on ClinicalTrials.gov

Tumor Kinase Inhibitor Concentrations Measured by PET

NACompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

February 28, 2017

Conditions
Disseminated Malignant Neoplasm
Interventions
OTHER

[11C] kinase inhibitor PET [15O]water PET and tumor biopsies.

\[11C\] kinase inhibitor PET (i.e. sorafenib and erlotinib in this study, with the aim to investigate others in future studies) and \[15O\]water PET will be performed before and after 2 weeks of treatment. Tumor biopsies will be performed before and after 2 weeks of therapy.

Trial Locations (1)

1081 HV

VU University Medical Center, Amsterdam

All Listed Sponsors
lead

Amsterdam UMC, location VUmc

OTHER

NCT02111889 - Tumor Kinase Inhibitor Concentrations Measured by PET | Biotech Hunter | Biotech Hunter